Cervical cancer is the second most common cancer in India among women in the age group of 15-44 years. Every year millions of women are diagnosed with cervical cancer as well as some other cancers and they also have very high mortality rates.
Pune Agencies. The Drugs Controller General of India (DCGI) on Tuesday approved the Serum Institute of India (SII) to market the indigenously developed vaccine against cervical cancer, QHPV. Quadrivalent Human Papillomavirus Vaccine (QHPV) is the first indigenous vaccine against cervical cancer in India. DCGI has approved the marketing of the serum after the recommendation of the subject expert committee on Kovid-19 on 15 June. After reviewing the clinical trial data of the vaccine, the government’s advisory committee NTAGI also approved QHPV.
Cervical cancer is the second most common cancer in India among women in the age group of 15-44 years. Every year millions of women are diagnosed with cervical cancer as well as some other cancers and they also have very high mortality rates. The Serum Institute, in its application to the DCGI, stated that the qHPV vaccine produces strong immunity against cervical cancer.
Vaccine can be launched before the end of the year: Sources
Sources close to news agency ANI said, “It is expected that the vaccine will be launched in the market before the end of the year.” QHPV will be India’s first indigenous vaccine against cervical cancer. Pune-based Serum Institute of India has applied for market authorization. Serum Institute of India applied after completing Phase 2/3 clinical trial in collaboration with Department of Biotechnology to ensure its early availability in the country.
Adar Poonawalla expressed happiness
Serum Institute of India CEO Adar Poonawalla made this announcement by tweeting. He wrote, ‘For the first time, an Indian HPV vaccine that is both affordable and accessible will be available for the treatment of cervical cancer in women. We look forward to launching it later this year and we thank DCGI, MoHFW_INDIA for giving the nod today.
The National Technical Advisory Group on Immunization (NTAGI) recently approved QHPV after reviewing clinical trial data for the vaccine.